case_images: PMC11109434_01
case_images: Cutaneous Squamous cell carcinoma Clinical Presentation. (A) Patient 1 (from left to right): Initial presentation at baseline; progression of disease after 3 months of pembrolizumab; partial response after 7 months of cetuximab. (B) Patient 3 (from left to right): Initial presentation at baseline; partial response after 2 months of cetuximab; complete response after 28 months of cetuximab.
case_images: fonc-14-1385094-g001.jpg
case_images: PMC11109434_03_fonc-14-1385094-g001.jpg
case_images: f1
case_images: Restaging scans at 28 months after cetuximab initiation demonstrated a CR, prompting discontinuation of treatment ( Figure 1B ).
case_images: PMC11109434_02
case_images: PMC11109434_03
case_images: Cutaneous Squamous cell carcinoma Clinical Presentation. (A) Patient 1 (from left to right): Initial presentation at baseline; progression of disease after 3 months of pembrolizumab; partial response after 7 months of cetuximab. (B) Patient 3 (from left to right): Initial presentation at baseline; partial response after 2 months of cetuximab; complete response after 28 months of cetuximab.
case_images: fonc-14-1385094-g001.jpg
case_images: PMC11109434_03_fonc-14-1385094-g001.jpg
case_images: f1
case_images: Restaging scans at 28 months after cetuximab initiation demonstrated a CR, prompting discontinuation of treatment ( Figure 1B ).